Literature DB >> 20218625

"Carba"-analogues of fentanyl are opioid receptor agonists.

Grazyna Weltrowska1, Nga N Chung, Carole Lemieux, Jianxin Guo, Yixin Lu, Brian C Wilkes, Peter W Schiller.   

Abstract

There is evidence to indicate that the Asp residue in the third transmembrane helix (TMH) of opioid receptors forms a salt bridge with the positively charged nitrogen of endogenous and exogenous opioid ligands. To further examine the role of this electrostatic interaction in receptor binding and activation, we synthesized "carba"-analogues of a published fentanyl analogue containing a 3-(guanidinomethyl)-benzyl group in place of the phenyl moiety attached to the ethylamido group (C. Dardonville et al., Bioorg. Med. Chem. 2006, 14, 6570-6580 (1)), in which the piperidine ring nitrogen was replaced with a carbon. As expected, the resulting cis and trans isomers (8a and 8b) showed reduced mu and kappa opioid receptor binding affinities as compared to 1 but, surprisingly, retained opioid full agonist activity with about half the potency of leucine-enkephalin in the guinea pig ileum assay. In conjunction with performed receptor docking studies, these results indicate that the electrostatic interaction of the protonated nitrogen in the piperidine ring of fentanyl analogues with the Asp residue in the third TMH is not a conditio sine qua non for opioid receptor activation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20218625      PMCID: PMC2848705          DOI: 10.1021/jm9019068

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  25 in total

1.  Unsulfated C-terminal 7-peptide of cholecystokinin: a new ligand of the opiate receptor.

Authors:  P W Schiller; A Lipton; D F Horrobin; M Bodanszky
Journal:  Biochem Biophys Res Commun       Date:  1978-12-29       Impact factor: 3.575

Review 2.  Weakly polar interactions in proteins.

Authors:  S K Burley; G A Petsko
Journal:  Adv Protein Chem       Date:  1988

3.  Complex of an active mu-opioid receptor with a cyclic peptide agonist modeled from experimental constraints.

Authors:  Carol B Fowler; Irina D Pogozheva; Andrei L Lomize; Harry LeVine; Henry I Mosberg
Journal:  Biochemistry       Date:  2004-12-21       Impact factor: 3.162

4.  Synthesis and antiparasitic and antitumor activity of 2, 4-diamino-6-(arylmethyl)-5,6,7,8-tetrahydroquinazoline analogues of piritrexim.

Authors:  A Rosowsky; A T Papoulis; R A Forsch; S F Queener
Journal:  J Med Chem       Date:  1999-03-25       Impact factor: 7.446

5.  Opioid activities of fragments of beta-endorphin and of its leucine65-analogue. Comparison of the binding properties of methionine- and leucine-enkephalin.

Authors:  A A Waterfield; F M Leslie; J A Lord; N Ling; H W Kosterlitz
Journal:  Eur J Pharmacol       Date:  1979-09-01       Impact factor: 4.432

6.  Molecular docking reveals a novel binding site model for fentanyl at the mu-opioid receptor.

Authors:  G Subramanian; M G Paterlini; P S Portoghese; D M Ferguson
Journal:  J Med Chem       Date:  2000-02-10       Impact factor: 7.446

7.  Conformation-activity relationships of cyclic dermorphin analogues.

Authors:  B C Wilkes; P W Schiller
Journal:  Biopolymers       Date:  1990-01       Impact factor: 2.505

8.  Novel ligands lacking a positive charge for the delta- and mu-opioid receptors.

Authors:  P W Schiller; I Berezowska; T M Nguyen; R Schmidt; C Lemieux; N N Chung; M L Falcone-Hindley; W Yao; J Liu; S Iwama; A B Smith; R Hirschmann
Journal:  J Med Chem       Date:  2000-02-24       Impact factor: 7.446

9.  Cyclic opioid peptide agonists and antagonists obtained via ring-closing metathesis.

Authors:  Irena Berezowska; Carole Lemieux; Nga N Chung; Brian C Wilkes; Peter W Schiller
Journal:  Chem Biol Drug Des       Date:  2009-08-20       Impact factor: 2.817

10.  Conversion of delta-, kappa- and mu-receptor selective opioid peptide agonists into delta-, kappa- and mu-selective antagonists.

Authors:  Peter W Schiller; Grazyna Weltrowska; Thi M-D Nguyen; Carole Lemieux; Nga N Chung; Yixin Lu
Journal:  Life Sci       Date:  2003-06-27       Impact factor: 5.037

View more
  7 in total

1.  Design synthesis and structure-activity relationship of 5-substituted (tetrahydronaphthalen-2yl)methyl with N-phenyl-N-(piperidin-2-yl)propionamide derivatives as opioid ligands.

Authors:  Srinivas Deekonda; David Rankin; Peg Davis; Josephine Lai; Todd W Vanderah; Frank Porecca; Victor J Hruby
Journal:  Bioorg Med Chem       Date:  2015-11-23       Impact factor: 3.641

Review 2.  Fentanyl-related compounds and derivatives: current status and future prospects for pharmaceutical applications.

Authors:  Ruben S Vardanyan; Victor J Hruby
Journal:  Future Med Chem       Date:  2014-03       Impact factor: 3.808

3.  Discovery of 5-substituted tetrahydronaphthalen-2yl-methyl with N-phenyl-N-(piperidin-4-yl)propionamide derivatives as potent opioid receptor ligands.

Authors:  Srinivas Deekonda; Lauren Wugalter; Vinod Kulkarni; David Rankin; Tally M Largent-Milnes; Peg Davis; Neemah M Bassirirad; Josephine Lai; Todd W Vanderah; Frank Porreca; Victor J Hruby
Journal:  Bioorg Med Chem       Date:  2015-08-04       Impact factor: 3.641

4.  'Carba'-carfentanil (trans isomer): a μ opioid receptor (MOR) partial agonist with a distinct binding mode.

Authors:  Grazyna Weltrowska; Carole Lemieux; Nga N Chung; Jason J Guo; Brian C Wilkes; Peter W Schiller
Journal:  Bioorg Med Chem       Date:  2014-07-29       Impact factor: 3.641

5.  Molecular dynamics of fentanyl bound to μ-opioid receptor.

Authors:  Piotr F J Lipiński; Małgorzata Jarończyk; Jan Cz Dobrowolski; Joanna Sadlej
Journal:  J Mol Model       Date:  2019-05-03       Impact factor: 1.810

6.  A systematic analysis of atomic protein-ligand interactions in the PDB.

Authors:  Renato Ferreira de Freitas; Matthieu Schapira
Journal:  Medchemcomm       Date:  2017-09-26       Impact factor: 3.597

Review 7.  Fentanyl Structure as a Scaffold for Opioid/Non-Opioid Multitarget Analgesics.

Authors:  Piotr F J Lipiński; Joanna Matalińska
Journal:  Int J Mol Sci       Date:  2022-03-02       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.